Related by context. All words. (Click for frequent words.) 78 Phase Ib 77 Phase 1b 76 Phase Ib clinical 75 Phase Ia 75 Phase III 75 multiple ascending dose 75 phase IIb 74 Phase 2b study 74 phase IIa 74 Phase 1b clinical 74 Phase 2a 74 phase Ib 73 Phase 2a clinical 73 Phase II 73 Phase IIa clinical 72 dose escalation Phase 72 Phase 1a clinical 71 Phase 2b 71 Phase Ib II 71 Phase 1b trial 71 phase IIa clinical 71 Phase 71 Phase IIa trial 71 Phase 2a trial 71 Phase IIIb clinical 71 Phase 2b trial 71 Phase Ib study 71 single ascending dose 71 Phase IIa 70 phase 2a 70 Phase IIb 70 Phase III clinical 70 dose escalation trial 70 Phase 2b clinical 70 phase IIb clinical 70 Phase IIb clinical 70 pharmacokinetic PK 70 Phase IIB 69 Phase #b/#a 69 multicenter Phase 69 dose escalation study 69 placebo controlled Phase 69 pharmacokinetics PK 69 Phase IIa trials 69 INCB# [001] 68 pivotal Phase III 68 ascending doses 68 multicenter Phase II 68 GALNS 68 PEG PAL 68 confirmatory Phase III 68 Phase IIb trials 68 Phase IIb trial 68 dose cohort 67 MEND CABG 67 randomized Phase III 67 alvespimycin 67 pharmacodynamic PD 67 Initiate Phase 67 viral kinetic 66 multicenter randomized placebo controlled 66 GLP toxicology studies 66 IIa trial 66 Phase Ib clinical trials 66 Phase IIIb 66 IIa clinical 66 phase Ib clinical 66 double blinded placebo 66 blinded randomized 66 BRIM2 66 preclinical efficacy 66 APEX PD 66 pharmacokinetic PK study 66 dose escalation clinical 66 Initiated Phase 66 randomized controlled Phase 65 TMC# [002] 65 BRIM3 65 dosing cohort 65 CR# vcMMAE 65 initiate Phase 2b 65 Phase 2b clinical trials 65 dose escalation 65 R#/MEM # 65 treatment naive genotype 65 ascending dose 65 TMC# C# 65 placebo controlled Phase III 65 phase IIb study 65 PEG Interferon lambda 65 multicenter phase 64 phase IIb trial 64 Phase 2b monotherapy 64 placebo controlled clinical 64 randomized Phase 64 IMA# 64 pharmacokinetic studies 64 ORMD 64 blinded randomized placebo controlled 64 IIa trials 64 masked placebo controlled 64 Phase #/#a 64 PRE SURGE 64 initiate Phase Ib 64 confirmatory Phase 3 64 elotuzumab 64 initiate Phase IIb 64 TASKi2 64 deforolimus 64 randomized Phase 2b 64 stated Michelle Berrey 64 ENDEAVOR IV 64 LUX Lung 64 GetGoal Phase III 64 registrational trial 64 ongoing Phase 1b 64 multicentre randomized 64 Phase 2a clinical trials 64 NO# [002] 64 Phase III pivotal 64 oral prodrug 64 Cloretazine ® 64 oral ridaforolimus 64 pharmacodynamic effects 64 Multiple Ascending Dose 64 Phase IIb III 64 assessing T DM1 63 ADVANCE PD 63 Plicera 63 dose cohorts 63 trodusquemine 63 initiate Phase 1b 63 Cloretazine R VNP#M 63 pivotal Phase 63 double blinded randomized 63 budesonide foam 63 dose dose escalation 63 pharmacokinetic 63 Randomized Phase 63 registrational 63 Pivotal Phase 63 initiate Phase IIa 63 glufosfamide 63 Phase #b/#a clinical 63 preclinical pharmacokinetic 63 RSD# oral 63 torezolid phosphate 63 cannabinor 63 confirmatory clinical 63 Phase IIb clinical trials 63 placebo controlled randomized 63 CIMZIA TM 63 pharmacokinetic PK profile 63 IMGN# 63 initiate Phase 63 Phase 2b randomized 63 safety tolerability 63 Pivotal Phase III 63 fosbretabulin 63 ganetespib 63 forodesine 63 Phase 1b dose escalation 63 teriflunomide 63 AP# [003] 62 Phase Ib IIa 62 randomized Phase IIb 62 tanespimycin 62 Phase IIb Trial 62 subcutaneously administered 62 CRLX# 62 blind randomized placebo 62 HuMax EGFr 62 placebo controlled 62 SUCCEED trial 62 NOX E# 62 Phase lll 62 Phase III Pivotal 62 tolerability 62 DermaVir Patch 62 Phase IIA 62 satraplatin Phase 62 axitinib 62 IND submission 62 Phase 1b clinical trials 62 lintuzumab 62 bendamustine 62 multicenter randomized controlled 62 BLA filing 62 PRIMO CABG 62 velafermin 62 dose escalation phase 62 dosing cohorts 62 evaluating mipomersen 62 clinical pharmacology studies 62 IDX# 62 Phase III clinical trials 62 lomitapide 62 Phase III trials 62 μg dose 62 pivotal bioequivalence 62 phase IIb III 62 mg/m2 cohort 62 PXD# 62 PRTX 62 mertansine 62 clinical trial 62 AZX# Phase 62 Phase III Clinical Trial 62 Traficet EN 62 thorough QT 62 Phase 2b Clinical Trial 62 Pivotal Trial 62 MERLIN TIMI 62 CHAMPION PCI 62 vidofludimus 62 JAK inhibitor 62 relapsed refractory multiple myeloma 62 HCV SPRINT 61 SPIRIT FIRST 61 APTIVUS 61 MEND CABG II 61 PSMA ADC 61 Cloretazine 61 administered subcutaneously 61 initiated Phase Ib 61 urocortin 2 61 riociguat 61 PA# [002] 61 solithromycin 61 nonclinical studies 61 TOLAMBA 61 prospective randomized placebo 61 Phase III confirmatory 61 multicenter randomized Phase 61 Phase1 61 PFO migraine 61 Zerenex 61 BLA submission 61 multicenter randomized double 61 ELACYT 61 Laquinimod 61 PRECiSE 61 CIMZIA ™ 61 blinded placebo controlled 61 PRT# 61 DB# [003] 61 Phase #/#a trial 61 ATL# [001] 61 maximally tolerated dose 61 Phase #b/#a trial 61 RE SURGE 61 telaprevir VX 61 Phase III placebo controlled 61 orally bioavailable 61 PDE4 inhibitor 61 Phase IIa clinical trials 61 prospective randomized controlled 61 sunitinib malate 61 relapsed MM 61 randomized placebo controlled 61 PRESEPT 61 #:# randomization 61 blind randomized 61 huC# DM4 61 rindopepimut 61 Exherin TM 61 pharmacodynamic 61 SCH # 61 IIb clinical trial 61 NP2 Enkephalin 61 PSN# [002] 61 tolerated dose MTD 61 trastuzumab emtansine T DM1 61 EURIDIS 61 AVADO 61 AIR CF2 61 Phase III randomized controlled 61 TAXUS ATLAS 61 Pharmacokinetic 61 prospectively defined 61 Archexin 61 pharmacodynamics PD 61 Phase III registrational 61 safety tolerability pharmacokinetic 61 randomized controlled clinical 61 ABSORB trial 61 COU AA 61 ENDEAVOR III 61 CLL8 61 azilsartan medoxomil 61 Commences Phase 61 tolevamer 61 RG# [001] 61 IND enabling 61 Phase III Clinical Trials 61 RE LY ® 61 Sym# 60 nab paclitaxel 60 IMPACT DCM 60 TEMSO 60 UPLYSO 60 randomized discontinuation trial 60 HCV RESPOND 2 60 LibiGel Phase III 60 Actilon 60 AIR CF1 60 CCX# 60 HuMax CD4 60 Saforis 60 brivaracetam 60 GAMMAGARD 60 Elagolix 60 CEQ# 60 TBC# 60 Allovectin 7 60 randomized #:# 60 pharmacokinetics 60 nucleotide analog 60 phase IIIb 60 PANVAC VF 60 docetaxel Taxotere R 60 Genz # 60 Panzem R NCD 60 midstage trials 60 ADAGIO study 60 CCR5 mAb 60 double blind placebo 60 LB# [003] 60 VNP#M 60 SAR# [004] 60 Pharmacokinetics PK 60 active comparator 60 TG# [001] 60 dose limiting toxicities 60 pharmacokinetic profile 60 Fx #A 60 safety tolerability pharmacokinetics 60 Phase 2b Study 60 elacytarabine 60 Androxal TM 60 pharmacodynamic profile 60 IMPACT IMmunotherapy 60 IIa clinical trial 60 TKB# 60 PD LID 60 Thorough QT 60 huN# DM1 60 LCP AtorFen 60 DAPT 60 TG MV 60 CONSERV 60 Bezielle 60 ruxolitinib 60 Testosterone MDTS ® 60 BCX# 60 CA4P 60 PRX # 60 BCIRG 60 Phenoptin 60 Pharmacokinetic PK 60 pomalidomide 60 pertuzumab 60 PEG SN# 60 generation PNP inhibitor 60 European Sepsis Trial 60 crizotinib PF # 60 investigational protease inhibitor 60 polymerase inhibitor 60 adecatumumab MT# 60 multicenter Phase III 60 Dacogen injection 60 HCD# [002] 60 Aclidinium 60 Amrubicin 60 celgosivir 60 laquinimod 60 PS# [001] 60 REG2 60 GOUT 60 Phase #/#a clinical 60 Proellex TM 60 prospective multicenter randomized 60 randomized controlled multicenter 60 RDEA# 60 GRNVAC1 60 oral FTY# 60 TASKi3 60 VICTOR E1 60 unblinding 60 Azedra 60 randomized blinded 60 randomized multicenter Phase III 60 LUMINATE 60 Zemplar Capsules 60 Dose escalation 60 CLIRS trial 60 teduglutide 60 favorable pharmacokinetic profile 60 APPRAISE 60 DSMB recommended 60 AIMM trial 60 OvaRex R 60 ritonavir boosted 60 randomized multicenter 60 baminercept 60 Phase III HEAT 60 fostamatinib 60 ANCHOR trial 60 II Clinical Trial 60 pafuramidine 60 AEGR 60 PEG IFN 60 GLPG# 60 CLIRS 60 AKT inhibitor 59 pharmacodynamics 59 ALISTA 59 MADIT II 59 nonrandomized 59 subcutaneous SC 59 Phase 2b kidney transplant 59 HGS ETR1 59 EOquin TM 59 evaluating RDEA# 59 Urocidin 59 Ceplene/IL-2 59 Vitaxin 59 NSABP B 59 Maximum Tolerated Dose 59 MAXY alpha 59 dose pharmacokinetic 59 Darusentan 59 inhibitor RG# 59 Forodesine HCl 59 NGX# 59 Omacetaxine 59 denufosol 59 eliglustat tartrate 59 elagolix 59 albiglutide 59 ISIS # 59 Achieves Primary Endpoint 59 QLT# 59 liposomal formulation 59 orally dosed 59 evaluating tivozanib 59 Meets Primary Endpoint 59 multicenter clinical 59 ritonavir boosting 59 TACI Ig 59 Kahalalide F 59 alemtuzumab Campath 59 multicentre 59 Phase IIb Clinical Trial 59 Ozarelix 59 adecatumumab 59 OvaRex ® MAb 59 Feasibility Trial 59 neratinib 59 randomized multicentre 59 telaprevir dosing 59 Aeroquin 59 treatment naïve genotype 59 Alzhemed TM 59 ularitide 59 trastuzumab DM1 59 MORAb 59 controlled multicenter 59 Xanafide 59 pharmacokinetic pharmacodynamic 59 oral rivaroxaban 59 melphalan prednisone 59 OncoVEX GM CSF 59 omacetaxine mepesuccinate 59 randomized multicenter trial 59 ofatumumab 59 IFN α 59 receptor tyrosine kinase inhibitor 59 confirmatory pivotal 59 GLP1 agonist 59 Valortim 59 clinical trials Multikine 59 Quinamed 59 prucalopride 59 #mg QD [002] 59 Confirmatory Phase 59 investigational humanized monoclonal antibody 59 PREOS R 59 XOMA 3AB 59 non nucleoside HCV 59 pharmacokinetic parameters 59 DLTs 59 trastuzumab DM1 T DM1 59 dexpramipexole 59 mcg dose 59 CLARITY study 59 Phase III randomized 59 XL# SAR# 59 AZILECT R 59 Tesetaxel 59 ORACLE MS 59 HspE7 59 XL# [003] 59 Pivotal Study 59 Phase Ib Clinical Trial 59 tolerability profile 59 antibody MAb 59 QD dosing 59 EDEMA3 59 ToGA 59 novel histone deacetylase 59 ZALBIN dosed 59 PREOS 59 dyskinesia PD LID 59 galiximab 59 Universal Flu Vaccine 59 Tarceva TM 59 omega interferon 59 rALLy clinical trial 59 FOLOTYN ® 59 CBLC# 59 AERAS-#/Crucell Ad# 59 midstage clinical 59 secondary efficacy endpoints 59 Mipomersen 59 PEARL SC 59 BrachySil TM 59 Phase III TRIST 59 REVIVE Diabetes 59 rALLy trial 59 ocrelizumab 59 aclidinium 59 Initiates Phase II 58 Alocrest 58 CG# [003] 58 Phase III Trial 58 volociximab 58 Phase III psoriasis 58 Phase 2a Study 58 Allovectin 7 R 58 Phase 2a Clinical Trial 58 controlled multicenter Phase 58 LCP Tacro 58 Fodosine 58 EchoCRT 58 aclidinium bromide 58 CUSTOM III 58 Aptivus ® 58 randomized controlled 58 Anturol TM 58 Blinatumomab 58 SYMMETRY trial 58 Pafuramidine 58 ILLUMINATE 58 intravenous dosing 58 BrachySil 58 dosage regimens 58 histone deacetylase HDAC inhibitor 58 DASISION 58 blinatumomab 58 Lovaxin C 58 Omnitarg 58 phase III ACCLAIM 58 R# #mg BID 58 enzastaurin 58 eltrombopag 58 Diamyd ® 58 TLK# 58 randomized clinical 58 ZYBRESTAT 58 triphendiol 58 CoFactor 58 SUTENT ® 58 Multimeric 58 LAF# 58 AEG# 58 HuMax CD# 58 KRN# 58 subcutaneous PRO 58 eprotirome 58 Phase III VISTA 58 ROCKET AF 58 OPT CHF 58 MIRCERA 58 Pimavanserin 58 valopicitabine 58 Trofex 58 velafermin belinostat 58 Daclizumab 58 ritonavir boosted danoprevir 58 Successfully Completes Phase 58 CCX# B 58 XL# XL# XL# 58 Capesaris 58 placebo controlled dose escalation 58 confirmatory Phase 58 multicenter placebo controlled 58 ARIKACE 58 opioid induced bowel dysfunction 58 Pharmacokinetic Study 58 GW# [003] 58 CRx 58 Triolex 58 tramiprosate Alzhemed TM 58 vosaroxin 58 sNDA submission 58 bardoxolone 58 oral methylnaltrexone 58 virus HCV protease inhibitor 58 Civacir 58 Fibrillex TM 58 multicenter dose escalation 58 Sapacitabine 58 randomized discontinuation 58 ZYBRESTAT fosbretabulin 58 diabetic neuropathic pain 58 viral kinetics 58 Initiates Phase 58 #mg/m# [001] 58 GSK# [001] 58 Phase 2a preventative 58 albinterferon alfa 2b 58 NVA# 58 Aurora kinase inhibitor 58 IMC A# 58 YONDELIS 58 Scopus Affiliation Identifier 58 TRO# 58 Randomized Evaluation 58 Pegasys plus Copegus 58 Protease Inhibitor 58 ACCEDE 58 intermittent dosing 58 SparVax TM 58 RELOVAIR ™ 58 refractory CLL 58 nalbuphine ER 58 rALLy 58 reslizumab 58 thymalfasin 58 tolerability pharmacokinetics 58 Factor VIIa 58 edoxaban 58 obatoclax 58 Aflibercept 58 MAP# 58 Randomized Phase II 58 CRMD# 58 Ostarine 58 bicifadine 58 STRIDE PD 58 peginesatide 58 includes TOLAMBA TM 58 RSD# 58 OncoVEX 58 prospective randomized multicenter 58 Vicriviroc 58 ALN TTR# 58 lumiliximab 58 novel VDA molecule 58 MEK inhibitor 58 Asentar 58 dose regimens 58 Phase IIa proof 58 RAV# 58 tesmilifene 58 Telatinib 58 Dextofisopam 58 HDAC Inhibitor 58 investigational compound 58 Aurexis 58 CLORETAZINE TM VNP#M 58 Chemophase 58 preclinical studies 58 evaluable subjects 58 subanalysis 58 labial herpes 58 highly immunogenic 58 posaconazole 58 inhaled AAT 58 TELCYTA 58 Clinical Study 58 atazanavir ritonavir 58 LEXIVA r 58 Aplidin 58 PHASE III 58 HGS ETR2 58 lead Aganocide compound 58 Phase III multicenter 58 RhuDex 58 dirucotide 58 octreotide implant 58 Ocrelizumab 58 Virulizin ® 58 depsipeptide 58 desvenlafaxine succinate 58 CAPACITY 58 sapacitabine 58 lorvotuzumab mertansine 58 AQ4N 58 TRX1 58 randomized double 58 resminostat 58 IIa clinical trials 58 Matrix Phase 2b 58 Pralatrexate 58 LE SN# 58 Clinical Trial Results 58 REMUNE R 58 bevirimat Study 57 VEGF Trap 57 BAL# [002] 57 Augment Injectable 57 Hsp# Inhibitor 57 Phase III Psoriasis 57 drug pipeline TAFA# 57 Annamycin 57 Zybrestat 57 MAA submission 57 L BLP# 57 alicaforsen enema 57 REG1 Anticoagulation System 57 VALOR trial 57 OLYMPIA registry 57 Japanese Encephalitis Vaccine 57 blind placebo controlled 57 Zenvia Phase III 57 HPTN 57 ALSYMPCA 57 AzaSite Plus 57 ALTU 57 Corlux 57 initiate multicenter 57 prospective multicenter 57 HGS# 57 immunosuppressive compound 57 Randomised 57 non nucleoside inhibitor 57 ALN VSP Phase 57 ACCLAIM II 57 Phase 2b Trial 57 LEP ETU 57 blind randomized controlled 57 AZX# 57 HCV protease inhibitor 57 Dose Ranging Study 57 Pivotal Trials 57 AeroLEF TM 57 tezampanel NGX# 57 placebo controlled clinical trials 57 FTY# fingolimod 57 mg/m2/day 57 VP# [004] 57 DEB# 57 MKC# MKC# PP 57 cilengitide 57 Panzem R 57 Antiviral Activity 57 CYT# QbG# 57 EOquin 57 BENLYSTA ® 57 maturation inhibitor 57 MIST II 57 antiviral efficacy 57 blind randomized multicenter 57 BR.# 57 MAGE A3 ASCI 57 PI3K/Akt pathway inhibitor 57 DSMB 57 KSP inhibitor 57 Pharmacokinetic studies 57 Vacc 4x 57 INCB# [002] 57 fluticasone furoate 57 paclitaxel poliglumex 57 cathepsin K inhibitor 57 nitazoxanide 57 EXPLORE Xa 57 MDS AML 57 ABSORB clinical 57 ataluren 57 daily subcutaneous injections 57 NN# [001] 57 preclinical toxicology 57 PHX# 57 Viramidine 57 dependent kinase inhibitor 57 catheter occlusion 57 efficacy endpoint 57 Troxatyl 57 PLK1 SNALP 57 integrase inhibitor 57 cancer neuroendocrine tumor 57 QNEXA 57 Trial Evaluating 57 unblinded 57 GSK# [002] 57 Phase IV 57 Spiegelmer ® 57 Imvamune R 57 Prostate AdenoCarcinoma Treatment 57 PROVENGE ® 57 ENRICH trial 57 tolerability profiles 57 vivo preclinical 57 Moli# 57 pharmacodynamic properties 57 Allovectin 7 ® 57 EFAPROXYN 57 label multicenter 57 relapsing multiple sclerosis 57 oral COTI 57 nucleoside analog 57 Parkinson disease levodopa induced 57 tgAAC# 57 cystinosis patients 57 Dyloject TM 57 ACTEMRA TM 57 Maximum Tolerated Dose MTD 57 oral picoplatin 57 selective androgen receptor modulator 57 Flutiform ™ 57 EndoTAG TM -1 57 pradefovir 57 designated HVTN 57 certolizumab 57 COMFORT II 57 MGd 57 Carfilzomib 57 tezampanel 57 DU #b 57 vicriviroc 57 bosutinib 57 generation NNRTI 57 UVIDEM 57 Enzastaurin 57 advanced carcinoid 57 ChronVac C ® 57 XmAb# 57 ALN RSV# 57 Denufosol 57 torezolid 57 Sorafenib HCC Assessment 57 oxymorphone ER 57 anti leukemic 57 VESTASYNC 57 Menerba 57 oral deforolimus 57 BOLDER II 57 Oglemilast 57 BNC# 57 orBec 57 palifosfamide Zymafos TM 57 Omacetaxine mepesuccinate 57 oral treprostinil 57 TPI ASM8 57 null responder HCV 57 Amigal 57 rilonacept 57 label dose escalation 57 Nasulin 57 lorcaserin Phase 57 FORTIS M trial 57 pharmacokinetics pharmacodynamics 57 RGB # 57 mipomersen 57 immunogenicity 57 multicenter 57 bosentan 57 MBP# [001] 57 IMC #B 57 BAY #-# 57 PENNVAX B 57 XP# XP# 57 RG# ITMN 57 lintuzumab SGN 57 beta 1a 57 heavily pretreated 57 ZYBRESTAT TM 57 amrubicin 57 AEZS 57 EVIZON 57 Anthim 57 alvimopan 57 maribavir 57 Randomized controlled 57 Urocortin 2 57 Inhalation Solution 57 bapineuzumab AAB 57 multicenter multinational 57 Tesmilifene 57 JunJing II 57 ENGAGE AF TIMI 57 generation URAT1 inhibitor 57 JAK2 inhibitor 57 CRp 57 IMPACT DCM clinical 57 farletuzumab 57 canakinumab 57 randomized #:#:# 57 Golimumab 57 monotherapy 57 RezularTM 57 Albuferon Phase 57 LEVADEX 57 mg kg dose 57 CLL SLL 57 Dacogen decitabine 57 metastatic hormone refractory 57 Phase III ThermoDox 57 compound INCB# 57 RhuDex ® 57 evaluating carfilzomib 57 ENESTnd 57 mGluR5 NAM 57 GRAVITAS trial 57 DOR# 57 BIIB# 56 mg dose 56 Valortim R 56 CALGB 56 Phase III ADT 56 SNT MC# 56 cariprazine 56 hypoxia activated prodrug 56 placebo controlled studies 56 apricitabine 56 Dose Escalation 56 CCR5 antagonist 56 Cethromycin 56 SPIRIT III 56 ANTEGREN 56 Synavive 56 intradermal injections 56 carfilzomib 56 Tamibarotene 56 XIENCE V Stent System 56 imetelstat GRN#L 56 NSABP 56 sunitinib 56 rhFVIIa 56 multicenter randomized 56 Prodarsan 56 initiate Phase 2a 56 omecamtiv mecarbil 56 Phase IIIb study 56 EMPHASIS HF trial 56 PARTNER Trial 56 Aplidin R 56 PF # [001] 56 Combination REOLYSIN R 56 Imprime PGG 56 ASA# 56 EDEMA4 56 safinamide 56 SIMPADICO 56 Liraglutide Effect 56 low dose cytarabine 56 clinical trials 56 eniluracil 56 mcg kg 56 Initiates Clinical 56 PEGylated interferon beta 1a 56 Bayer HealthCare Onyx Pharmaceuticals 56 multicenter prospective 56 APTIVUS r 56 RESTORE CLI trial 56 DDP# 56 RE LY 56 LAB CGRP 56 Thiovir 56 Study Evaluating 56 BLOOM DM 56 generation antisense inhibitor 56 Aryplase 56 NABTT 56 GRN#L 56 CELVAPAN H#N# 56 MoxDuo ® 56 analgesic efficacy 56 pramlintide metreleptin 56 Zerenex ™ 56 lixisenatide 56 ATL/TV# 56 NEBIDO 56 Teriflunomide 56 VELCADE melphalan 56 LymphoStat B Phase 56 Bicifadine 56 #mg dose [002] 56 OMNARIS Nasal Spray 56 aflibercept 56 pharmacokinetic characteristics 56 Dasatinib 56 ARDIS 56 rPA anthrax vaccine 56 Metastatic Melanoma 56 recurrent glioblastoma multiforme 56 GV# [001]